The DOI matches its Crossref record; 154 of the 155 references it cites were found in a registry or an index.
Idiosyncratic drug hepatotoxicity
Abstract
The occurrence of idiosyncratic drug hepatotoxicity is a major problem in all phases of clinical drug development and the most frequent cause of post-marketing warnings and withdrawals. This review examines the clinical signatures of this problem, signals predictive of its occurrence (particularly of more frequent, reversible, low-grade injury) and the role of monitoring in prevention by examining several recent examples (for example, troglitazone). In addition, the failure of preclinical toxicology to predict idiosyncratic reactions, and what can be done to improve this problem, is discussed. Finally, our current understanding of the pathophysiology of experimental drug hepatotoxicity is examined, focusing on acetaminophen, particularly with respect to the role of the innate immune system and control of cell-death pathways, which might provide targets for exploration and identification of risk factors and mechanisms in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The current drug development process suffers from a high failure rate during clinical trials, which is partly due to inadequacy of animal models to accurately predict the toxic side-effects of drugs in humans [1,2].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [2]
In the citing paper
“Drug-induced liver injury (DILI) is a common adverse drug reaction (ADR), and it can lead to liver failure and even death.[1][2][3]”
From Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (2019) · cites this paper as [1]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Acetaminophen-induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136547 · Cited by 1,092
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Research works printed but not linked: 3
- Nelson, S. D. & Bruschi, S. A. in Drug-Induced Liver Disease (eds Kaplowitz, N. & DeLeve, L.) 287–325 (Marcel Dekker, New York, 2003).
- Chien, J. Y., Thummel, K. E. & Slattery, J. T. Pharmakinetic consequence of induction of CYP2E1 by ligand stabilization. Drug Metab. Dispos. 25, 1165–1175 (1997).
- Liu, Z. -X. & Kaplowitz, N. in Clinics in Liver Disease 6, 467–486 (Elsevier, 2002).
Cited by
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Self-citationMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationDeterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting
Ma, X., Qu, X., Zhu, W., Li, Y.-S., Yuan, S., Zhang, H., Liu, J., Wang, P., Lai, C. S. E., Zanella, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524510113 · Cited by 872
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
A liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615
“The following parameters were collected for all the enrolled patients: (1) Demographics; (2) disease history and alcohol consumption history; (3) information about the implicated drug that might have caused the liver injury, including the time of onset after starting the drug and the time of recovery after stopping th…”
BackgroundMethodO’Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0091-3 · Cited by 609
Begriche, K., Massart, J., Robin, M.-A., Borgne-Sanchez, A., & Fromenty, B. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.006 · Cited by 555
Hanawa, N., Shinohara, M., Saberi, B., Gaarde, W. A., Han, D., & Kaplowitz, N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708916200 · Cited by 527
Self-citationCellular Imaging Predictions of Clinical Drug-Induced Liver Injury
Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., & de Graaf, D. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn109 · Cited by 492
Abboud, G., & Kaplowitz, N. (2007) · Drug Safety · doi:10.2165/00002018-200730040-00001 · Cited by 479
Self-citationDrug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
Hepatocyte Death: A Clear and Present Danger
Malhi, H., Guicciardi, M. E., & Gores, G. J. (2010) · Physiological Reviews · doi:10.1152/physrev.00061.2009 · Cited by 477
Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., Day, C. P., Ruiz–Cabello, F., Donaldson, P. T., Stephens, C., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.04.001 · Cited by 442
ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
Role of liver sinusoidal endothelial cells in liver diseases
Gracia-Sancho, J., Caparrós, E., Fernández-Iglesias, A., & Francés, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00411-3 · Cited by 410
Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity
Russmann, S., Kullak-Ublick, G., & Grattagliano, I. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803097 · Cited by 412
Ma, X., Liu, J., Zhu, W., Tang, M., Lawrence, N., Yu, C., Gou, M., & Chen, S. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.011 · Cited by 401
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D., Zineh, I., Giacomini, K. M., & Krauss, R. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2423 · Cited by 391
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury
Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., Wright, T. M., Meyer, J., & Paulding, C. A. (2010) · Nature Genetics · doi:10.1038/ng.632 · Cited by 388
Organ-on-a-chip platforms for studying drug delivery systems
Bhise, N. S., Ribas, J., Manoharan, V., Zhang, Y. S., Polini, A., Massa, S., Dokmeci, M. R., & Khademhosseini, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.004 · Cited by 381
Molecular mechanisms underlying chemical liver injury
Gu, X., & Manautou, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002110 · Cited by 381
Idiosyncratic Adverse Reactions to Antiepileptic Drugs
Zaccara, G., Franciotta, D., & Perucca, E. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01041.x · Cited by 364
Muscular exercise can cause highly pathological liver function tests in healthy men
Pettersson, J., Hindorf, U., Persson, P., Bengtsson, T., Malmqvist, U., Werkström, V., & Ekelund, M. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03001.x · Cited by 357
Liver organoids: from basic research to therapeutic applications
Prior, N., Inacio, P., & Huch, M. (2019) · Gut · doi:10.1136/gutjnl-2019-319256 · Cited by 356
The importance of plasma protein binding in drug discovery
Trainor, G. L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.51 · Cited by 348
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347
Katarey, D., & Verma, S. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s104 · Cited by 331
Mechanisms of drug-induced liver injury
Yuan, L., & Kaplowitz, N. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.002 · Cited by 322
Self-citationOrgans-on-chips: breaking the in vitro impasse
Meer, A. D. V. D., & Berg, A. V. D. (2012) · Integrative Biology · doi:10.1039/c2ib00176d · Cited by 314
CSH guidelines for the diagnosis and treatment of drug-induced liver injury
Drug-induced Liver Injury (DILI) Study Group, Yu, Y.-C., Chinese Society of Hepatology (CSH), Chinese Medical Association (CMA), Mao, Y.-M., Chen, C.-W., Chen, J.-J., Chen, J., Cong, W.-M., Ding, Y., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9793-2 · Cited by 254
Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis
Iorga, A., Dara, L., & Kaplowitz, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051018 · Cited by 268
Self-citationDrug-induced liver injury: Summary of a single topic clinical research conference
Watkins, P. B., & Seeff, L. B. (2006) · Hepatology · doi:10.1002/hep.21095 · Cited by 279
Sinusoidal Obstruction Syndrome (Hepatic Veno-Occlusive Disease)
Fan, C. Q., & Crawford, J. M. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.10.002 · Cited by 274
Spraggs, C. F., Budde, L. R., Briley, L. P., Bing, N., Cox, C. J., King, K. S., Whittaker, J. C., Mooser, V. E., Preston, A. J., Stein, S. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3197 · Cited by 275
Antidepressant-Induced Liver Injury: A Review for Clinicians
Voican, C. S., Corruble, E., Naveau, S., & Perlemuter, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13050709 · Cited by 275
Stieger, B. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_5 · Cited by 269
Drug-induced autoimmune-like hepatitis
Czaja, A. J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1611-4 · Cited by 235
Kostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., Naughton, B., & Roth, A. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.01.012 · Cited by 262
Drug-induced Acute Liver Failure
Lee, W. M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.001 · Cited by 257
Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., & Okazaki, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027797 · Cited by 251
Human myeloperoxidase in innate and acquired immunity
Arnhold, J., & Flemmig, J. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.04.008 · Cited by 251
Senior, J. R. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.108 · Cited by 247
Stickel, F., Patsenker, E., & Schuppan, D. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.08.002 · Cited by 243
Hirawat, S., Welch, E. M., Elfring, G. L., Northcutt, V. J., Paushkin, S., Hwang, S., Leonard, E. M., Almstead, N. G., Ju, W., Peltz, S. W., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006297140 · Cited by 242
Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro
Leite, S. B., Roosens, T., El Taghdouini, A., Mannaerts, I., Smout, A. J., Najimi, M., Sokal, E., Noor, F., Chesne, C., & van Grunsven, L. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.026 · Cited by 234
Mitochondrial abnormalities—A link to idiosyncratic drug hepatotoxicity?
Boelsterli, U. A., & Lim, P. L. K. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.013 · Cited by 232
Martin-Murphy, B. V., Holt, M. P., & Ju, C. (2010) · Toxicology Letters · doi:10.1016/j.toxlet.2009.11.016 · Cited by 226
Acetaminophen-induced Liver Injury: from Animal Models to Humans
(2014) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00014 · Cited by 226
Therapeutic and diagnostic potential of nanomaterials for enhanced biomedical applications
Abd Elkodous, M., El-Sayyad, G. S., Abdelrahman, I. Y., El-Bastawisy, H. S., Mohamed, A. E., Mosallam, F. M., Nasser, H. A., Gobara, M., Baraka, A., Elsayed, M. A., et al. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.05.008 · Cited by 219
Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity
Beger, R. D., Sun, J., & Schnackenberg, L. K. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.11.019 · Cited by 216
Pathophysiological Basis for Antioxidant Therapy in Chronic Liver Disease
Medina, J., & Moreno-Otero, R. (2005) · Drugs · doi:10.2165/00003495-200565170-00003 · Cited by 216
Hepatic safety of antibiotics used in primary care
Andrade, R. J., & Tulkens, P. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr159 · Cited by 213
Kidambi, S., Yarmush, R. S., Novik, E., Chao, P., Yarmush, M. L., & Nahmias, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906820106 · Cited by 213
Use of Micropatterned Cocultures to Detect Compounds That Cause Drug-Induced Liver Injury in Humans
Khetani, S. R., Kanchagar, C., Ukairo, O., Krzyzewski, S., Moore, A., Shi, J., Aoyama, S., Aleo, M., & Will, Y. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kfs326 · Cited by 208
Interaction of Occupational and Personal Risk Factors in Workforce Health and Safety
Schulte, P. A., Pandalai, S., Wulsin, V., & Chun, H. (2012) · American Journal of Public Health · doi:10.2105/ajph.2011.300249 · Cited by 205
Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010–2019)
Ke, L., Lu, C., Shen, R., Lu, T., Ma, B., & Hua, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00842 · Cited by 204
Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
Win, S., Than, T. A., Han, D., Petrovic, L. M., & Kaplowitz, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276089 · Cited by 197
Self-citationHan, D., Dara, L., Win, S., Than, T. A., Yuan, L., Abbasi, S. Q., Liu, Z.-X., & Kaplowitz, N. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.009 · Cited by 196
Self-citationWare, B. R., Berger, D. R., & Khetani, S. R. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv048 · Cited by 195
Lucena, M. I., Andrade, R. J., Martínez, C., Ulzurrun, E., García‐Martín, E., Borraz, Y., Fernández, M. C., Romero‐Gomez, M., Castiella, A., Planas, R., et al. (2008) · Hepatology · doi:10.1002/hep.22370 · Cited by 195
Curcumin and Liver Disease: from Chemistry to Medicine
Nabavi, S. F., Daglia, M., Moghaddam, A. H., Habtemariam, S., & Nabavi, S. M. (2014) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12047 · Cited by 192
An Update on Drug-induced Liver Injury
Devarbhavi, H. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2012.05.002 · Cited by 191
Diagnosis, management and prevention of drug-induced liver injury
Verma, S., & Kaplowitz, N. (2009) · Gut · doi:10.1136/gut.2008.163675 · Cited by 192
Self-citationVorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
Harrill, A. H., Watkins, P. B., Su, S., Ross, P. K., Harbourt, D. E., Stylianou, I. M., Boorman, G. A., Russo, M. W., Sackler, R. S., Harris, S. C., et al. (2009) · Genome Research · doi:10.1101/gr.090241.108 · Cited by 177
Clinical Syndromes and Consequences of Antiretroviral-Related Hepatotoxicity5, 1, 3
Núñez, M. (2010) · Hepatology · doi:10.1002/hep.23716 · Cited by 178
Multi-cellular 3D human primary liver cell culture elevates metabolic activity under fluidic flow
Esch, M. B., Prot, J.-M., Wang, Y. I., Miller, P., Llamas-Vidales, J. R., Naughton, B. A., Applegate, D. R., & Shuler, M. L. (2015) · Lab on a Chip · doi:10.1039/c5lc00237k · Cited by 173
Bioengineered Liver Models for Drug Testing and Cell Differentiation Studies
Underhill, G. H., & Khetani, S. R. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.012 · Cited by 171
GARCÍA‐CORTÉS, M., LUCENA, M. I., PACHKORIA, K., BORRAZ, Y., HIDALGO, R., ANDRADE, R. J., & ON BEHALF OF THE SPANISH GROUP FOR THE STUDY OF DRUG‐INDUCED LIVER DISEASE (GRUPO DE ESTUDIO PARA LAS HEPATOPATÍAS ASOCIADAS A MEDICAMENTOS, G. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03655.x · Cited by 143
Hepatotoxicity related to antirheumatic drugs
Aithal, G. P. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.214 · Cited by 170
Developing Structure−Activity Relationships for the Prediction of Hepatotoxicity
Greene, N., Fisk, L., Naven, R. T., Note, R. R., Patel, M. L., & Pelletier, D. J. (2010) · Chemical Research in Toxicology · doi:10.1021/tx1000865 · Cited by 171
Redox Regulation of Tumor Necrosis Factor Signaling
Han, D., Ybanez, M. D., Ahmadi, S., Yeh, K., & Kaplowitz, N. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2611 · Cited by 168
Self-citationDrug-induced liver injury: present and future
Suk, K. T., & Kim, D. J. (2012) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2012.18.3.249 · Cited by 168
Activity-based fluorescence probes for pathophysiological peroxynitrite fluxes
Mao, Z., Xiong, J., Wang, P., An, J., Zhang, F., Liu, Z., & Seung Kim, J. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214356 · Cited by 165
Lucena, M. I., Andrade, R. J., Fernández, M. C., Pachkoria, K., Pelaez, G., Durán, J. A., Villar, M., Rodrigo, L., Romero‐Gomez, M., Planas, R., et al. (2006) · Hepatology · doi:10.1002/hep.21324 · Cited by 166
Mechanisms of Drug-Induced Liver Disease
Gunawan, B. K., & Kaplowitz, N. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.06.001 · Cited by 165
Self-citation3D Printed Tissue Models: Present and Future
Jang, J., Yi, H.-G., & Cho, D.-W. (2016) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00129 · Cited by 161
Naturally-Derived Biomaterials for Tissue Engineering Applications
Brovold, M., Almeida, J. I., Pla-Palacín, I., Sainz-Arnal, P., Sánchez-Romero, N., Rivas, J. J., Almeida, H., Dachary, P. R., Serrano-Aulló, T., Soker, S., et al. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-0947-2_23 · Cited by 160
Baillie, T. A., & Rettie, A. E. (2011) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-089 · Cited by 160
Baillie, T. A. (2006) · Chemical Research in Toxicology · doi:10.1021/tx060062o · Cited by 160
Evaluation of Drugs With Specific Organ Toxicities in Organ-Specific Cell Lines
Lin, Z., & Will, Y. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfr339 · Cited by 158
Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity—Two Villains or One?
Roth, R. A., & Ganey, P. E. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162651 · Cited by 157
Liver-Kidney-on-Chip To Study Toxicity of Drug Metabolites
Theobald, J., Ghanem, A., Wallisch, P., Banaeiyan, A. A., Andrade-Navarro, M. A., Taškova, K., Haltmeier, M., Kurtz, A., Becker, H., Reuter, S., et al. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00417 · Cited by 166
Khan, H. Z., Ullah, H., & Nabavi, S. M. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.12.002 · Cited by 174
Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury
Medina-Caliz, I., Robles-Diaz, M., Garcia-Muñoz, B., Stephens, C., Ortega-Alonso, A., Garcia-Cortes, M., González-Jimenez, A., Sanabria-Cabrera, J. A., Moreno, I., Fernandez, M. C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.003 · Cited by 140
Self-citationDeng, X., Stachlewitz, R. F., Liguori, M. J., Blomme, E. A. G., Waring, J. F., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., & Roth, R. A. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110247 · Cited by 157
In vitro platforms for evaluating liver toxicity
Bale, S. S., Vernetti, L. A., Senutovitch, N., Jindal, R., Hegde, M., Gough, A., McCarty, W. J., Bakan, A., Bhushan, A., Shun, T. Y., et al. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214531872 · Cited by 163
In Vitro Culture, Drug Sensitivity, and Transcriptome of Plasmodium Vivax Hypnozoites
Gural, N., Mâncio-Silva, L., Miller, A. B., Galstian, A., Butty, V. L., Levine, S. S., Patrapuvich, R., Desai, S. P., Mikolajczak, S. A., Kappe, S. H. I., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.01.002 · Cited by 170
A Decade of Toxicogenomic Research and Its Contribution to Toxicological Science
Chen, M., Zhang, M., Borlak, J. T., & Tong, W. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs223 · Cited by 165
Yang, S., & Kar, S. (2023) · Artificial Intelligence Chemistry · doi:10.1016/j.aichem.2023.100011 · Cited by 190
Design and fabrication of a scalable liver-lobule-on-a-chip microphysiological platform
Banaeiyan, A. A., Theobald, J., Paukštytė, J., Wölfl, S., Adiels, C. B., & Goksör, M. (2017) · Biofabrication · doi:10.1088/1758-5090/9/1/015014 · Cited by 172
Assessment of Emerging Biomarkers of Liver Injury in Human Subjects
Schomaker, S., Warner, R. L., Bock, J., Johnson, K. J., Potter, D., Winkle, J. V., & Aubrecht, J. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft009 · Cited by 153
Metadata
- Authors
- Kaplowitz, N.
- Affiliations
- University of Southern California (US)
- Corresponding author
- Kaplowitz, Neil
- ORCID
- Kaplowitz, Neil
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-06
- Volume
- 4
- Issue
- 6
- Pages
- 489-499
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2017783406
- Cited by
- 1,054
- References
- 155
- Citations by year
- 2026: 29 · 2025: 35 · 2024: 35 · 2023: 44 · 2022: 31 · 2021: 49 · 2020: 45 · 2019: 48 · 2018: 54 · 2017: 66 · 2016: 72 · 2015: 55 · 2014: 64 · 2013: 57 · 2012: 52
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced liver injury, troglitazone, preclinical toxicology, hepatotoxicity prediction, pharmacovigilance, acetaminophen hepatotoxicity, innate immune system, cell death pathways, drug withdrawal, post-marketing surveillance
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Liver, Liver Diseases, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.